Maxigen Biotech

Maxigen Biotech Equity

The The Equity of Maxigen Biotech (1783.TW) as of Oct 20, 2026 is 1.54 B TWD. In the previous year, The Equity was 1.38 B TWD — a change of 11.82% (higher).

Equity

1.54 BTWD

YoY

11.82%

Last updated:

In 2025, Maxigen Biotech's equity was 1.54 B TWD, a 11.82% increase from the 1.38 B TWD equity in the previous year.

The Maxigen Biotech Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
842.98 M TWD
Jan 1, 2019
851.32 M TWD
Jan 1, 2020
860.23 M TWD
Jan 1, 2021
1.14 B TWD
Jan 1, 2022
1.30 B TWD
Jan 1, 2023
1.36 B TWD
Jan 1, 2024
1.38 B TWD
Jan 1, 2025
1.54 B TWD
The Maxigen Biotech Equity history
YEAREquityYoY
1.54 BTWD+11.82%
1.38 BTWD+1.03%
1.36 BTWD+5.05%
1.30 BTWD+13.48%
1.14 BTWD+32.72%
860.23 MTWD+1.05%
851.32 MTWD+0.99%
842.98 MTWD+5.87%
796.25 MTWD+1.90%
781.38 MTWD-5.84%
829.86 MTWD-5.38%
877.01 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Maxigen Biotech Stock analysis

What does Maxigen Biotech do? Maxigen Biotech Inc is a biotechnology company that was founded in 2000. The company, based in San Francisco, California, specializes in the development and production of biotechnological products and solutions. The company's goal is to lead in the biotechnology industry and have a positive impact on the health and well-being of people. To achieve its goals, the company has specialized in four business areas. The first business area is the research and development of new biotechnological products. The company has a team of scientists who work continuously on new innovative technologies and products. The company has already brought several products to market that have been very successful in the biotechnology industry. The second business area is the production of biotechnological products. The company has its own production facility equipped with state-of-the-art technologies. Here, the company's products are manufactured and delivered to customers worldwide. The third business area is the distribution of biotechnological products. The company has built a large distribution network to distribute its products in different parts of the world. The company works closely with pharmacies, laboratories, and hospitals to ensure that its products are made accessible to people. The fourth business area is the application of biotechnological products. The company works closely with doctors and healthcare facilities to ensure that its products are used in medical practice. The company is committed to using its products to improve the health and well-being of people worldwide. Maxigen Biotech Inc has introduced some remarkable products to the market in its history. One of the company's most important products is a highly effective antibiotic used to fight bacterial infections. The company has also developed a medication for the treatment of hypertension that is in high demand worldwide. Additionally, the company has developed a range of products for the treatment of cancer and other serious illnesses. The company has also made a significant contribution to public health. The company has developed technology to lower cholesterol levels in the blood, which can help prevent cardiovascular diseases. The company has also worked on the development of vaccines against infectious diseases that are still prevalent in some regions of the world. Maxigen Biotech Inc has received numerous awards and recognition in its history. The company is known for its innovation and high quality in the production of its products. The company is an example of how the biotechnology industry can contribute to improving the health and well-being of people worldwide. In summary, Maxigen Biotech Inc is a biotechnology company that specializes in the development and production of biotechnological products and solutions. The company has specialized in four business areas: research and development of new products, production of biotechnological products, distribution of biotechnological products, and application of biotechnological products. The company has introduced some remarkable products to the market in its history and has made a significant contribution to public health. The company has received numerous awards and recognition and is an example of excellence in the biotechnology industry. Maxigen Biotech is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Maxigen Biotech's Equity

Maxigen Biotech's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Maxigen Biotech's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Maxigen Biotech's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Maxigen Biotech's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Maxigen Biotech’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Maxigen Biotech stock

The Equity of Maxigen Biotech is 1.54 B TWD in 2025.

The Equity of Maxigen Biotech changed from 1.38 B TWD to 1.54 B TWD, representing a 11.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Maxigen Biotech since 2006 – with annual values, charts, and detailed analysis.

The Equity's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Maxigen Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Maxigen Biotech

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Maxigen Biotech